AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 4 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A nasally administered vaccine against Shigella flexneri, the most common cause of dysentery, shows promise against the pathogen in humans and warrants further investigation, say researchers working in the United States.
"We studied the safety and immunogenicity of a Shigella flexneri 2a vaccine comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins - proteosomes - in normal, healthy adults," said L.F. Fries and colleagues at Intellivax, Inc., Baltimore.
They administered various doses of the proteosome-S. flexneri vaccine delivered by intranasal spray in a dose-escalating regimen of 0.1, 0.4, 1.0, and 1.5 mg of protein.
The most common reactions reported, rhinorrhea and nasal stuffiness, were mild and self-limiting ("Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults," Infection and Immunity, July 2001;69(7):4545-53).
The vaccine elicited specific immunoglobulin A (IgA), IgG, and IgM antibodies to S. flexneri 2a LPS in a dose-responsive manner, and at higher doses, those increases were fivefold for IgA and IgG and two- to threefold for IgM, reported Fries and coworkers. Elevated serum antibody levels ...
Source: HighBeam Research, Mucosal Vaccine Generates Immune Response On Par With Live...